Compare PEB & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | MLYS |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2009 | 2023 |
| Metric | PEB | MLYS |
|---|---|---|
| Price | $18.33 | $25.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $13.30 | ★ $48.67 |
| AVG Volume (30 Days) | ★ 1.9M | 726.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,475,544,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.53 | N/A |
| 52 Week Low | $9.99 | $14.94 |
| 52 Week High | $19.93 | $47.65 |
| Indicator | PEB | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 48.72 | 45.57 |
| Support Level | $18.35 | $25.53 |
| Resistance Level | $19.73 | $30.90 |
| Average True Range (ATR) | 0.48 | 1.08 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 69.78 | 30.25 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.